<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448447</url>
  </required_header>
  <id_info>
    <org_study_id>Mammosite ML</org_study_id>
    <nct_id>NCT01448447</nct_id>
  </id_info>
  <brief_title>Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®</brief_title>
  <acronym>Mammosite ML</acronym>
  <official_title>Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Radiation Therapy Delivery System as the Sole Method of Radiation Therapy or as a Boost for Early Stage Breast Cancer and Ductal Carcinoma In Situ of the Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the local control rate, cosmetic results, and complication rates of&#xD;
      breast brachytherapy delivered using the MammoSite-ML® when used as the sole method of&#xD;
      radiation therapy or as a boost technique for patients with stage I-II carcinoma of the&#xD;
      breast (&lt; 3 cm), (non-lobular histology) treated with lumpectomy with histologically negative&#xD;
      surgical margins by at least 2 mm, negative axillary lymph nodes, and DCIS.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        -  For selected patients with stage I breast carcinoma and Ductal Carcinoma In Situ (DCIS),&#xD;
           radiation therapy delivered with brachytherapy alone using the MammoSite-ML® is&#xD;
           technically feasible and reproducible with acceptable complication rates.&#xD;
&#xD;
        -  Cosmetic results after brachytherapy will be similar to that obtained after traditional&#xD;
           whole breast external beam radiation therapy.&#xD;
&#xD;
        -  Local tumor control rate in the breast after brachytherapy will be similar to that of&#xD;
           conventional external beam radiation therapy, with less inconvenience and potentially&#xD;
           less cost to the patient, given the selection criteria which minimize the risk of&#xD;
           clinically significant multicentric or extensive residual carcinoma following&#xD;
           lumpectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ipsilateral Recurrence Rate</measure>
    <time_frame>5 years</time_frame>
    <description>Local recurrence is defined as either invasive or non-invasive breast cancer recurrence within the target volume.&#xD;
Elsewhere recurrence is defined as either invasive or non-invasive breast cancer recurrence outside of the target volume.&#xD;
Local control rate will be evaluated by imaging techniques, physical exam and biopsy, if applicable.&#xD;
Measured as a count of participants experiencing recurrence, i.e. each subject experiencing ipsilateral tumor recurrence within 5 years = 1, and each subject with no ipsilateral tumor recurrence within 5 years = 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Results</measure>
    <time_frame>6 months after treatment, then annually for 5 years</time_frame>
    <description>Evaluation of cosmetic results as judged by the patient, surgeon, and radiation oncologist at stated follow up intervals. Serial photographs will be obtained. The cosmetic results will be assessed using the four category Harvard Scale definitions: Excellent - The treated breast looks essentially the same as the opposite breast Good - Minimal but identifiable effects of radiation on the treated breast Fair - Significant effects of radiation on the treated breast Poor - Severe normal tissue sequelae secondary to irradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Measured Through Adverse Event Incidence</measure>
    <time_frame>during therapy, 6 weeks after completion of therapy, and additionally as needed</time_frame>
    <description>The incidence of serious adverse events will be calculated. Adverse events reviewed for device harm/toxicity include skin redness, breast pain, infections, breast swelling, and rib fractures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ductal Carcinoma in Situ</condition>
  <arm_group>
    <arm_group_label>Sole method</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mammosite ML</intervention_name>
    <description>34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days</description>
    <arm_group_label>Sole method</arm_group_label>
    <other_name>HDR Brachytherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mammosite ML</intervention_name>
    <description>5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)</description>
    <arm_group_label>Boost</arm_group_label>
    <other_name>HDR Brachytherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women,age of at least 45 years&#xD;
&#xD;
          -  Zubrod performance status of 0-2&#xD;
&#xD;
          -  AJCC Stage I-II (T1-T2, N0 M0) breast cancer&#xD;
&#xD;
          -  Maximum tumor dimension &lt; 3 cm&#xD;
&#xD;
          -  Invasive ductal, medullary, papillary, tubular, colloid (mucinous) histologies&#xD;
&#xD;
          -  Unifocal breast cancer&#xD;
&#xD;
          -  Unilateral breast cancer (no synchronous or previous contralateral breast cancer)&#xD;
&#xD;
          -  Lumpectomy with negative surgical margins by at least 2 mm or re-excision specimen&#xD;
             with negative surgical margins by at least 2 mm&#xD;
&#xD;
          -  Ductal Carcinoma In-Situ&#xD;
&#xD;
          -  Negative axillary lymph nodes for invasive breast cancer (sentinel node biopsy or&#xD;
             standard level I-II dissection with &gt; 6 nodes removed)&#xD;
&#xD;
          -  Time interval from final breast surgery to brachytherapy loading less than 8 weeks&#xD;
&#xD;
          -  At least 2 mm of breast tissue between the skin and the MammoSite® balloon&#xD;
             surface(prefer &gt; 5 mm)&#xD;
&#xD;
          -  If chemotherapy is planned, it must begin no earlier that 2 weeks following completion&#xD;
             of radiation therapy. If chemotherapy is first, a minimum of 2 weeks from the last&#xD;
             cycle must elapse prior to the start of radiation therapy.&#xD;
&#xD;
          -  Signed study-specific consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Invasive lobular histology&#xD;
&#xD;
          -  Non-epithelial breast malignancies such as sarcoma or lymphoma&#xD;
&#xD;
          -  Multifocal or multicentric invasive carcinoma&#xD;
&#xD;
          -  Extensive intraductal component (EIC)&#xD;
&#xD;
          -  Paget's disease of the nipple&#xD;
&#xD;
          -  Skin involvement by tumor, regardless of tumor size&#xD;
&#xD;
          -  Positive axillary lymph nodes&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Collagen vascular disease (scleroderma)&#xD;
&#xD;
          -  Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown&#xD;
             effects of RT on lactating females (negative pregnancy test for women of child-bearing&#xD;
             age)&#xD;
&#xD;
          -  Any previously treated or synchronous contralateral breast carcinoma&#xD;
&#xD;
          -  Patients with psychiatric or addictive disorder that would preclude obtaining informed&#xD;
             Consent&#xD;
&#xD;
          -  Men&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bethany G Sleckman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Hospital St. Louis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy Clinic St. Louis Cancer and Breast Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <results_first_submitted>May 18, 2021</results_first_submitted>
  <results_first_submitted_qc>June 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2021</results_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Research</investigator_affiliation>
    <investigator_full_name>Robert Frazier, MD</investigator_full_name>
    <investigator_title>MD, Radiation Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sole Method</title>
          <description>patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days</description>
        </group>
        <group group_id="P2">
          <title>Boost</title>
          <description>patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>20 patients were enrolled within sole method arm, no patients were enrolled in boost method arm</population>
      <group_list>
        <group group_id="B1">
          <title>Sole Method</title>
          <description>patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days</description>
        </group>
        <group group_id="B2">
          <title>Boost</title>
          <description>patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Recurrence Rate</title>
        <description>Local recurrence is defined as either invasive or non-invasive breast cancer recurrence within the target volume.&#xD;
Elsewhere recurrence is defined as either invasive or non-invasive breast cancer recurrence outside of the target volume.&#xD;
Local control rate will be evaluated by imaging techniques, physical exam and biopsy, if applicable.&#xD;
Measured as a count of participants experiencing recurrence, i.e. each subject experiencing ipsilateral tumor recurrence within 5 years = 1, and each subject with no ipsilateral tumor recurrence within 5 years = 0</description>
        <time_frame>5 years</time_frame>
        <population>11 patients within sole method arm were lost to follow-up prior to 5 year follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Sole Method</title>
            <description>patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days</description>
          </group>
          <group group_id="O2">
            <title>Boost</title>
            <description>patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Recurrence Rate</title>
          <description>Local recurrence is defined as either invasive or non-invasive breast cancer recurrence within the target volume.&#xD;
Elsewhere recurrence is defined as either invasive or non-invasive breast cancer recurrence outside of the target volume.&#xD;
Local control rate will be evaluated by imaging techniques, physical exam and biopsy, if applicable.&#xD;
Measured as a count of participants experiencing recurrence, i.e. each subject experiencing ipsilateral tumor recurrence within 5 years = 1, and each subject with no ipsilateral tumor recurrence within 5 years = 0</description>
          <population>11 patients within sole method arm were lost to follow-up prior to 5 year follow-up period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmetic Results</title>
        <description>Evaluation of cosmetic results as judged by the patient, surgeon, and radiation oncologist at stated follow up intervals. Serial photographs will be obtained. The cosmetic results will be assessed using the four category Harvard Scale definitions: Excellent - The treated breast looks essentially the same as the opposite breast Good - Minimal but identifiable effects of radiation on the treated breast Fair - Significant effects of radiation on the treated breast Poor - Severe normal tissue sequelae secondary to irradiation</description>
        <time_frame>6 months after treatment, then annually for 5 years</time_frame>
        <population>No patient information was collected for boost method arm as no patients were enrolled into boost method arm.&#xD;
11 participants in sole method arm were lost to follow-up over 5 year period.</population>
        <group_list>
          <group group_id="O1">
            <title>Sole Method</title>
            <description>patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days</description>
          </group>
          <group group_id="O2">
            <title>Boost</title>
            <description>patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)</description>
          </group>
        </group_list>
        <measure>
          <title>Cosmetic Results</title>
          <description>Evaluation of cosmetic results as judged by the patient, surgeon, and radiation oncologist at stated follow up intervals. Serial photographs will be obtained. The cosmetic results will be assessed using the four category Harvard Scale definitions: Excellent - The treated breast looks essentially the same as the opposite breast Good - Minimal but identifiable effects of radiation on the treated breast Fair - Significant effects of radiation on the treated breast Poor - Severe normal tissue sequelae secondary to irradiation</description>
          <population>No patient information was collected for boost method arm as no patients were enrolled into boost method arm.&#xD;
11 participants in sole method arm were lost to follow-up over 5 year period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of pts with &quot;excellent&quot; cosmetic results, 1 year post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;good&quot; cosmetic results, 1 year post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;fair&quot; cosmetic results, 1 year post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;poor&quot; cosmetic results, 1 year post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;excellent&quot; cosmetic results, 2 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;good&quot; cosmetic results, 2 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;fair&quot; cosmetic results, 2 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;poor&quot; cosmetic results, 2 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;excellent&quot; cosmetic results, 3 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;good&quot; cosmetic results, 3 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;fair&quot; cosmetic results, 3 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;poor&quot; cosmetic results, 3 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;excellent&quot; cosmetic results, 4 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;good&quot; cosmetic results, 4 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;fair&quot; cosmetic results, 4 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;poor&quot; cosmetic results, 4 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;excellent&quot; cosmetic results, 5 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;good&quot; cosmetic results, 5 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;fair&quot; cosmetic results, 5 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pts with &quot;poor&quot; cosmetic results, 5 years post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Measured Through Adverse Event Incidence</title>
        <description>The incidence of serious adverse events will be calculated. Adverse events reviewed for device harm/toxicity include skin redness, breast pain, infections, breast swelling, and rib fractures.</description>
        <time_frame>during therapy, 6 weeks after completion of therapy, and additionally as needed</time_frame>
        <population>No patient information was collected for boost method arm as no patients were enrolled into boost method arm of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Sole Method</title>
            <description>patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days</description>
          </group>
          <group group_id="O2">
            <title>Boost</title>
            <description>patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Measured Through Adverse Event Incidence</title>
          <description>The incidence of serious adverse events will be calculated. Adverse events reviewed for device harm/toxicity include skin redness, breast pain, infections, breast swelling, and rib fractures.</description>
          <population>No patient information was collected for boost method arm as no patients were enrolled into boost method arm of study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events will be collected during follow-up visits non-systematically over the course of 5 years beginning from procedure.</time_frame>
      <desc>Adverse event information not collected from boost method arm patients, as there were no patients enrolled for the boost method arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sole Method</title>
          <description>patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days</description>
        </group>
        <group group_id="E2">
          <title>Boost</title>
          <description>patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS&#xD;
Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Frazier</name_or_title>
      <organization>Mercy</organization>
      <phone>314-251-6844</phone>
      <email>Robert.Frazier@mercy.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

